Hubei Hongyuan Pharmaceutical Technology Co., Ltd. (SHE:301246)
China · Delayed Price · Currency is CNY 21.30
-0.48 (-2.20%)
Feb 13, 2026, 4:00 PM EST
SHE:301246 Revenue
Hubei Hongyuan Pharmaceutical Technology had revenue of 434.52M CNY in the quarter ending September 30, 2025, with 2.45% growth. This brings the company's revenue in the last twelve months to 1.77B, down -2.91% year-over-year. In the year 2024, Hubei Hongyuan Pharmaceutical Technology had annual revenue of 1.77B, down -13.83%.
Revenue (ttm)
1.77B
Revenue Growth
-2.91%
P/S Ratio
4.74
Revenue / Employee
814.00K
Employees
2,169
Market Cap
8.37B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.77B | -284.16M | -13.83% |
| Dec 31, 2023 | 2.05B | -8.84M | -0.43% |
| Jan 1, 2023 | 2.06B | 485.86M | 30.79% |
| Jan 1, 2022 | 1.58B | 274.92M | 21.10% |
| Jan 1, 2021 | 1.30B | -271.47M | -17.24% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Harbin Pharmaceutical Group | 15.94B |
| Renhe Pharmacy Co.,Ltd | 3.76B |
| Tianjin Ringpu Bio-Technology | 3.37B |
| Jiangsu Kanion Pharmaceutical | 3.13B |
| Zhejiang Tianyu Pharmaceutical | 2.99B |
| Sunflower Pharmaceutical Group Co.,Ltd | 2.09B |
| Guilin Sanjin Pharmaceutical | 2.08B |
| Sichuan Huiyu Pharmaceutical | 984.29M |